Atricure, INC

AtriCure announced second quarter 2026 financial results, showcasing a 12.8% year-over-year revenue increase to $153.6 million and a significant improvement in profitability.

AtriCure, Inc. stockholders approved amendments to the 2023 Stock Incentive Plan and 2018 Employee Stock Purchase Plan, increasing authorized shares.

AtriCure announced first quarter 2026 financial results, showcasing a 14.3% year-over-year revenue increase to $141.2 million and improved profitability with net income of $0.1 million.

AtriCure, Inc. extended its credit facility by three years, reduced interest rates, and reported strong preliminary 2025 financial results with optimistic 2026 guidance.

AtriCure, Inc. reported strong third quarter 2025 financial results with worldwide revenue increasing 15.8% year-over-year and raised its full-year financial outlook.

AtriCure, Inc. reported strong third quarter 2025 financial results with significant revenue growth and improved profitability, leading to an increased full-year financial outlook.

AtriCure Inc. announced its Q2 2026 financial results, showcasing a 13.5% increase in worldwide revenue to $294.9 million, driven by strong performance in key product lines.

AtriCure Inc. announced its first quarter 2026 financial results, showcasing a 14.3% increase in worldwide revenue to $141.2 million, driven by strong performance in its pain and appendage management product lines.

AtriCure, Inc. reported significantly reduced net losses and strong revenue growth for the third quarter and first nine months of 2025, driven by key product lines and international expansion.

AtriCure, Inc. announced robust revenue growth and a significant reduction in net loss for the second quarter and first half of 2025, fueled by strong performance in appendage and pain management product lines and advancements in clinical trials.

AtriCure, Inc. announces a 13.6% increase in worldwide revenue for Q1 2025, driven by product innovation, clinical science, and physician education.

AtriCure's Q3 2024 results show a 17.9% increase in worldwide revenue, fueled by product innovation and global market expansion.

AtriCure, Inc. announced its 2025 annual results, reporting a 14.9% increase in worldwide revenue to $534.5 million, driven by strong adoption of pain management, open ablation, and appendage management products, while net loss significantly narrowed to $11.4 million.

AtriCure's 2024 10-K filing reveals a 16.5% increase in revenue, fueled by product innovation, clinical science investments, and physician education.

AtriCure, Inc. has issued stock incentive plans and restricted stock awards to employees, detailing vesting schedules, forfeiture conditions, and compliance requirements.

Michael H Carrel, President, CEO, & Director and a Director of AtriCure, Inc., reported multiple transactions in common stock on July 30, 2026.

Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc., sold 6,000 shares of common stock on July 28, 2026 for $38.88 per share.

Sven Wehrwein, a Director of AtriCure, Inc., sold 25,000 shares of common stock on July 28, 2026 for $37.84 per share.

Justin J Noznesky, Chief Mktg & Strategy Officer of AtriCure, Inc., sold 6,182 shares of common stock on July 29, 2026 for $38.80 per share.

AtriCure, Inc. CEO Michael H. Carrel acquired company shares through the Employee Stock Purchase Plan on June 30, 2026.

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, acquired 636 shares of common stock through the company's Employee Stock Purchase Plan.

AtriCure, Inc. has released its 2026 proxy statement detailing proposals for director elections, executive compensation, and increases to equity incentive plans.

AtriCure urges stockholders to approve its Say-on-Pay proposal, addressing concerns raised by ISS and Glass Lewis regarding executive compensation, particularly the CEO's special performance share unit award.

AtriCure, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

AtriCure, Inc. has announced its 2025 Annual Meeting of Stockholders to be held virtually on May 19, 2025, and is seeking stockholder approval for several proposals, including an amendment to the 2023 Stock Incentive Plan.

AtriCure is urging its stockholders to vote in favor of its Say-on-Pay proposal at the upcoming Annual Meeting, despite a recommendation against it from proxy advisory firm Glass Lewis.

AtriCure urges stockholders to approve a proposal to amend its certificate of incorporation to limit officer liability, countering a recommendation from Glass Lewis.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 6.8% of AtriCure, Inc. common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.08% of AtriCure Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.51% of AtriCure Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in AtriCure Inc. following an internal organizational realignment.

Macquarie Group Limited and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 4.60% in AtriCure Inc's common shares.

BlackRock, Inc. has reported an increased beneficial ownership of 7.8% in AtriCure Inc.'s common stock, holding 3,862,837 shares as of September 30, 2025.